- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07947199
Erector Spinae Plane Block Versus External Oblique Intercostal Plus Lateral External Oblique Muscle Plane Block in Laparoscopic Living Donor Nephrectomy
Comparison of Erector Spinae Plane Block and Combined External Oblique Intercostal and Lateral External Oblique Muscle Plane Blocks for Postoperative Analgesia After Laparoscopic Living Donor Nephrectomy: A Prospective, Randomized, Double-Blind Trial
Living kidney donors undergoing laparoscopic donor nephrectomy will be randomized to receive either an erector spinae plane block (ESPB) or a combination of external oblique intercostal (EOI) and lateral external oblique muscle plane (lateral EXOP) blocks at the end of surgery. The study aims to compare postoperative pain scores, opioid consumption, rescue analgesic requirement and postoperative nausea and vomiting between the two groups.
Studienübersicht
Status
Detaillierte Beschreibung
Laparoscopic living donor nephrectomy is associated with less postoperative pain than open surgery; however, trocar sites, the extraction incision and flank dissection can still cause substantial somatic and visceral pain. Results regarding the analgesic efficacy of ESPB in laparoscopic donor nephrectomy are conflicting, and sensory spread to the anterolateral abdominal wall after ESPB appears variable. The EOI block targets the lateral and anterior cutaneous branches of the T6-T10 intercostal nerves, and the lateral EXOP block targets the lateral cutaneous branches of T11-T12. As the trocar sites and the extraction incision are located on the anterolateral abdominal wall, we hypothesize that the combination of EOI and lateral EXOP blocks may provide more consistent analgesia than ESPB.
All donors will undergo transperitoneal laparoscopic donor nephrectomy, and the kidney will be extracted through the lower lateral trocar site as standard. Anesthesia will be induced with propofol, fentanyl and rocuronium and maintained with sevoflurane and remifentanil. Thirty minutes before the end of surgery, all patients will receive 1 g IV paracetamol, 100 mg IV tramadol and 8 mg IV ondansetron.
All blocks will be performed unilaterally on the surgical side under ultrasound guidance, after skin closure and before emergence from anesthesia, with the patient in the surgical lateral decubitus position. Each group will receive a total of 40 mL of 0.25% bupivacaine.
Group ESPB: the block will be performed at the T9 level, 2-3 cm lateral to the spinous process, with 40 mL of 0.25% bupivacaine injected deep to the erector spinae muscle.
Group EOI + lateral EXOP: the EOI block will be performed at the 6th rib level between the midclavicular and anterior axillary lines, with 20 mL of 0.25% bupivacaine injected between the external oblique and intercostal muscles. The lateral EXOP block will be performed on the mid-axillary line between the costal margin and the iliac crest, with 20 mL of 0.25% bupivacaine injected superficial to the external oblique muscle.
Postoperatively, all patients will receive 1 g IV paracetamol every 8 hours and fentanyl via IV patient-controlled analgesia (10 µg bolus, 10-minute lockout, no background infusion). Patients with NRS ≥4 despite PCA use will receive 0.5 mg/kg IV pethidine as rescue analgesia.
Because all blocks will be performed under general anesthesia, patients will be unaware of their group allocation. To maintain blinding, a standard dressing will be applied to all three potential block sites (paravertebral at T9, 6th rib level and lateral abdomen) in every patient. All postoperative assessments will be performed by an independent anesthesiologist who is not involved in block administration and is blinded to group allocation.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: ayse ince, assist proff
- Telefonnummer: 0905366774988
- E-Mail: drayseince@gmail.com
Studieren Sie die Kontaktsicherung
- Name: Bahadir Ciftci, Assoc. Prof.
- Telefonnummer: 0905343736865
- E-Mail: bahadirciftci25@gmail.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Living kidney donors aged 18-65 years ASA physical status I-II Scheduled for elective pure transperitoneal laparoscopic donor nephrectomy Written informed consent
Exclusion Criteria:
Chronic pain or chronic opioid use Infection at the block site Allergy to local anesthetics Coagulopathy or anticoagulant use Body weight <50 kg Pregnancy Inability to use the NRS or PCA device Refusal to participate
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Group ESPB
Unilateral ultrasound-guided ESPB at T9 on the surgical side with 40 mL of 0.25% bupivacaine, performed at the end of surgery before emergence. |
Unilateral ultrasound-guided erector spinae plane block performed on the surgical side at the T9 level after skin closure and before emergence from general anesthesia, with the patient in the lateral decubitus position. A linear probe will be placed 2-3 cm lateral to the spinous process in a parasagittal orientation. The needle will be advanced in-plane in a cranio-caudal direction until its tip lies between the erector spinae muscle and the transverse process. After hydrodissection with 5 mL of saline, 40 mL of 0.25% bupivacaine will be injected.
Andere Namen:
All patients will receive 1 g IV paracetamol and 100 mg IV tramadol 30 minutes before the end of surgery. Postoperatively, 1 g IV paracetamol will be given every 8 hours, and fentanyl will be delivered via IV patient-controlled analgesia (10 µg bolus, 10-minute lockout, no background infusion). Patients with NRS ≥4 despite PCA will receive 0.5 mg/kg IV pethidine as rescue analgesia.
Andere Namen:
|
|
Experimental: Group EOI and Lateral EXOP Combination
External oblique intercostal block and lateral external oblique muscle plane block combination will be applied. Unilateral ultrasound-guided EOI block at the 6th rib level (20 mL of 0.25% bupivacaine) and lateral EXOP block (20 mL of 0.25% bupivacaine) on the surgical side, performed at the end of surgery before emergence. |
All patients will receive 1 g IV paracetamol and 100 mg IV tramadol 30 minutes before the end of surgery. Postoperatively, 1 g IV paracetamol will be given every 8 hours, and fentanyl will be delivered via IV patient-controlled analgesia (10 µg bolus, 10-minute lockout, no background infusion). Patients with NRS ≥4 despite PCA will receive 0.5 mg/kg IV pethidine as rescue analgesia.
Andere Namen:
Unilateral ultrasound-guided blocks will be performed on the surgical side after skin closure and before emergence from general anesthesia. EOI block: the probe will be placed at the 6th rib level between the midclavicular and anterior axillary lines in a paramedian sagittal-oblique orientation, and 20 mL of 0.25% bupivacaine will be injected between the external oblique and intercostal muscles. Lateral EXOP block: the probe will be placed on the mid-axillary line between the costal margin and the iliac crest, and 20 mL of 0.25% bupivacaine will be injected superficial to the external oblique muscle. Correct needle tip position is confirmed with 5 mL of saline before each injection. Total volume: 40 mL of 0.25% bupivacaine.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pain score at 8th hour
Zeitfenster: 8 hours after PACU admission
|
Pain intensity at rest assessed with the Numeric Rating Scale (0 = no pain, 10 = worst imaginable pain) |
8 hours after PACU admission
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cumulative fentanyl consumption
Zeitfenster: 0-24 hours postoperatively
|
Total fentanyl given via IV PCA (µg). |
0-24 hours postoperatively
|
|
Pain scores at rest and on coughing
Zeitfenster: 0, 2, 4, 8, 12 and 24 hours postoperatively.
|
Pain scores at rest and on coughing will be recorded based on NRS (0-10). |
0, 2, 4, 8, 12 and 24 hours postoperatively.
|
|
Time to first rescue analgesic
Zeitfenster: 0-24 hours postoperatively.
|
Time from PACU admission to the first pethidine dose given for NRS ≥4. |
0-24 hours postoperatively.
|
|
Incidence of postoperative nausea and vomiting.
Zeitfenster: 0-24 hours postoperatively.
|
Number of patients with any nausea or vomiting episode will be recorded. |
0-24 hours postoperatively.
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Chin KJ, El-Boghdadly K. Mechanisms of action of the erector spinae plane (ESP) block: a narrative review. Can J Anaesth. 2021 Mar;68(3):387-408. doi: 10.1007/s12630-020-01875-2. Epub 2021 Jan 6.
- Ergun M, Berkers AW, van der Jagt MF, Langenhuijsen JF, van Ozdemir-Brunschot D, van der Vliet JA, D'Ancona FC, Warle MC. Components of pain assessment after laparoscopic donor nephrectomy. Acta Anaesthesiol Scand. 2014 Feb;58(2):219-22. doi: 10.1111/aas.12236. Epub 2013 Dec 6.
- Ozkalayci O, Karakaya MA, Yenigun Y, Cetin S, Darcin K, Akyollu B, Arpali E, Kocak B, Gurkan Y. Effects of erector spinae plane block on opioid consumption in patients undergoing hand-assisted laparoscopic donor nephrectomy: a randomized controlled trial. Minerva Anestesiol. 2024 Mar;90(3):154-161. doi: 10.23736/S0375-9393.23.17706-6. Epub 2024 Feb 2.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Schmerzen
- Neurologische Manifestationen
- Erkrankungen des Nervensystems
- Postoperative Komplikationen
- Pathologische Prozesse
- Neurobehaviorale Manifestationen
- Wahrnehmungsstörungen
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Schmerzen, postoperativ
- Agnosie
- Organische Chemikalien
- Lipide
- Anilides
- Amides
- Anilinverbindungen
- Amine
- Acetanilide
- Alkohole
- Cyclohexanole
- Hexanole
- Fettalkohole
- Dimethylamine
- Methylamine
- Acetaminophen
- Tramadol
Andere Studien-ID-Nummern
- Medipol 9
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
There is no plan to make individual participant data available
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .